biostudies-literatureLeighl NBNCATS NIH HHSFoundation for the National Institutes of HealthNational Cancer InstituteNCI NIH HHSFriends of Cancer ResearchAstraZenecae002973https://www.ebi.ac.uk/biostudies/studies/S-EPMC8386207biostudies-literatureUnknown9(8)<h4>Introduction</h4>S1400F is a non-match substudy of Lung Cancer Master Protocol (Lung-MAP) evaluating the immunotherapy combination of durvalumab and tremelimumab to overcome resistance to anti-programmed death ligand 1 (PD-(L)1) therapy in patients with advanced squamous lung carcinoma (sq non-small-cell lung cancer (NSCLC)).<h4>Methods</h4>Patients with previously treated sqNSCLC with disease progression after anti-PD-(L)1 monotherapy, who did not qualify for any active molecularly targeted Lung-MAP substudies, were eligible. Patients received tremelimumab 75 mg plus durvalumab 1500 mg once every 28 days for four cycles then durvalumab alone every 28 days until disease progression. The primary endpoint was the objective response rate (RECIST V.1.1). Primary and acquired resistance cohJournal for immunotherapy of cancerPhase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760).PMC8386207U10 CA180819U10 CA180863U10 CA180820U10CA180888, U10CA180819, U10CA180820, U10CA180821through the Foundation for the National InstitutesU10 CA180868U10 CA180821P30 CA093373U10 CA180888UL1 TR001863P30 CA014236UG1 CA233340Stinchcombe TESchwartz LHCrawford JHirsch FRWade JLMinichiello KMiao JHerbst RSIrvin WJRamalingam SSPapadimitrakopoulou VABradley JDGandara DRReddy SCRedman MWKelly KLeighl NBMack PCRizvi NfalsePhase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760).<h4>Introduction</h4>S1400F is a non-match substudy of Lung Cancer Master Protocol (Lung-MAP) evaluating the immunotherapy combination of durvalumab and tremelimumab to overcome resistance to anti-programmed death ligand 1 (PD-(L)1) therapy in patients with advanced squamous lung carcinoma (sq non-small-cell lung cancer (NSCLC)).<h4>Methods</h4>Patients with previously treated sqNSCLC with disease progression after anti-PD-(L)1 monotherapy, who did not qualify for any active molecularly targeted Lung-MAP substudies, were eligible. Patients received tremelimumab 75 mg plus durvalumab 1500 mg once every 28 days for four cycles then durvalumab alone every 28 days until disease progression. The primary endpoint was the objective response rate (RECIST V.1.1). Primary and acquired resistance coh2021-01-01T00:00:00Z2021 Aug2026-06-15T06:07:13.423Z2026-06-15T03:09:05.773ZS-EPMC83862073442933210.1136/jitc-2021-002973